Dermatology News

The addition of azithromycin to an ivermectin mass drug administration, or MDA, had a similar effect as ivermectin alone for treating scabies and impetigo, according to published study results in Clinical Infectious Diseases.

Fireworks are a ubiquitous presence among Fourth of July celebrations; however, these bright and colorful displays pose a danger to children who may want to handle these dangerous products.

An otherwise healthy 10-month-old male presented to clinic with a several-week history of rash. His parents reported that the rash started on the right arm and axillae, and spread down the torso to the right leg (Figures 1 and 2). The family reported a fever a few weeks before the rash started but no associated respiratory or gastrointestinal symptoms. The rash was asymptomatic and had not been treated. On examination, he had numerous 2- to 3-mm erythematous, scaling papules on the right axillae extending to the arms, legs, and trunk.

A 5-year-old male was brought to his primary provider for evaluation of a slowly growing, painless lump in the patient’s right proximal thigh. The problem was first noted a few weeks earlier but may have been there longer, and it appears to be slowly growing in size. The diagnosis of impetigo was made, and the patient was given a prescription for cephalexin (Keflex, Flynn Pharma) without improvement. It was soon noted that there was some intermittent discharge of a small amount of clear fluid from the center of the lesion (Figure 1). The material was swabbed and sent for Gram stain and culture, and a course of clindamycin was given. Both the Gram stain and culture were negative, and the clindamycin had no benefit.

Skin-to-skin contact between parents and newborns — also known as kangaroo care — has been shown in studies improve children’s health and development, but it can also expose NICU patients to Staphylococcus aureus colonization and infection. A three-part intervention that included skin cleansing reduced the incidence of these infections, according to research presented at the annual conference of the Association for Professionals in Infection Control and Epidemiology, or APIC.

Atopic dermatitis in children and adults can improve with the treatment of a solution containing Roseomonas mucosa, which decreases the severity of the disease and reduces the rate of Staphylococcus aureus colonization in children, according to findings from a phase 1 and 2 trial.

People who inject drugs are around 16 times more likely to develop an invasive MRSA infection compared with others, with cases in this population rising from 4.1% to 9.2% from 2011 to 2016, according to findings published in MMWR.

Hemangeol was found to have a good overall safety profile as treatment for healthy children with infantile hemangioma, according to a study using a nationwide claims database in France.

Sanofi and Regeneron’s drug Dupixent led to clearer skin in most patients in phase 3 trial involving 12- to 17-year-olds with moderate-to-severe atopic dermatitis, according to a press release from the company.

The skin of children with early-onset atopic dermatitis exhibits significantly different phenotypes when compared with the skin of adults with a long-standing history with the disease, according to research published in The Journal of Allergy and Clinical Immunology.